drugset / Trial / NCT00365352

XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

NCT00365352

Phase 3 Completed 325 enrolled XenoPort, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

Timeline

Start
2006-08
Primary completion
2007-12
Completion
2007-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule 600 mg Oral
Subject gabapentin enacarbil Small molecule 1200 mg Oral